Raynaud, Florence

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 903

Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises

Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology

PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and Cancer

Cited by 543

Effect of sleep deprivation on the human metabolome

Davies, S. K., Ang, J. E., Revell, V. L., Holmes, B., Mann, A., Robertson, F. P., Cui, N., Middleton, B., Ackermann, K., Kayser, M., et al. (2014) · Proceedings of the National Academy of Sciences

Circadian rhythm and melatoninSleep and Work-Related Fatigue

Cited by 527

Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy

Ryan, C. J., Smith, M. R., Fong, L., Rosenberg, J. E., Kantoff, P., Raynaud, F., Martins, V., Lee, G., Kheoh, T., Kim, J., et al. (2010) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 396

Interlaboratory Reproducibility of a Targeted Metabolomics Platform for Analysis of Human Serum and Plasma

Siskos, A. P., Jain, P., Römisch-Margl, W., Bennett, M., Achaintre, D., Asad, Y., Marney, L., Richardson, L., Koulman, A., Griffin, J. L., et al. (2017) · Analytical Chemistry

Metabolomics and Mass Spectrometry StudiesClinical Laboratory Practices and Quality Control

Cited by 269

Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease

Hill, R. M., Kuijper, S., Lindsey, J. C., Petrie, K., Schwalbe, E. C., Barker, K., Boult, J. K. R., Williamson, D., Ahmad, Z., Hallsworth, A., et al. (2015) · Cancer Cell

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 210

Identification of Human Plasma Metabolites Exhibiting Time-of-Day Variation Using an Untargeted Liquid Chromatography–Mass Spectrometry Metabolomic Approach

Ang, J. E., Revell, V., Mann, A., Mäntele, S., Otway, D. T., Johnston, J. D., Thumser, A. E., Skene, D. J., & Raynaud, F. (2012) · Chronobiology International

Metabolomics and Mass Spectrometry StudiesCircadian rhythm and melatonin

Cited by 138

Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening

Czodrowski, P., Mallinger, A., Wienke, D., Esdar, C., Pöschke, O., Busch, M., Rohdich, F., Eccles, S. A., Ortiz-Ruiz, M.-J., Schneider, R., et al. (2016) · Journal of Medicinal Chemistry

Heterocyclic Compound Synthesis and BioactivityComputational Drug Discovery Methods

Cited by 123

Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders

Bellenie, B. R., Cheung, K.-M. J., Varela, A., Pierrat, O. A., Collie, G. W., Box, G. M., Bright, M. D., Gowan, S., Hayes, A., Rodrigues, M. J., et al. (2020) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsHeterocyclic Compound Synthesis and Bioactivity

Cited by 74